SXL
ISEE

Summit X LLC’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Summit X LLC’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,000
Closed -$2K – 239
2018
Q3 		$2K Buy
+5,000
New +$12.5K ﹤0.01% 228
2018
Q1 		– Sell
-10,000
Closed -$7K – 198
2017
Q4 		$7K Buy
+10,000
New +$28.1K ﹤0.01% 179

Other funds holding ISEE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Summit X LLC's ISEE Position: Q1 2022 in Review

Summit X LLC sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2022, closing a stake of 11,350 shares — an estimated $188K sold.

Summit X LLC first reported a position in ISEE in Q4 2017 and held it in 17 quarters. The position peaked at $285K in Q4 2019. 163 funds tracked by Wall St. Rank hold ISEE as of Q1 2022.

  • Summit X LLC reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Summit X LLC sold 11,350 IVERIC bio, Inc. Common Stock shares in Q1 2022, an estimated $188K.
  • Summit X LLC first reported a position in IVERIC bio, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Summit X LLC's IVERIC bio, Inc. Common Stock position peaked at $285K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2022.

Based on Summit X LLC's 13F filing for Q1 2022, filed 5 May 2022.